Surveillance Seems Safe for Some Intermediate Risk Prostate CA

This article originally appeared here.
Share this content:
Surveillance Seems Safe for Some Intermediate Risk Prostate CA
Surveillance Seems Safe for Some Intermediate Risk Prostate CA

THURSDAY, April 14, 2016 (HealthDay News) -- For men with prostate cancer, active surveillance seems safe for those at low risk and for select patients at intermediate risk, according to a study published in The Journal of Urology.

Toshihiro Yamamoto, M.D., from the University of Toronto, and colleagues conducted a single-center, prospective cohort study involving men with prostate cancer initially treated with an expectant approach. The patients were followed for metastasis-free survival during a median of 6.3 years.

The researchers found that metastasis developed in 30 of the 980 patients (3.1 percent), including 14 of 211 classified at intermediate risk. Metastases developed in bone and lymph nodes in 18 and 13 patients, respectively. Independent predictors of metastasis included prostate specific antigen doubling time of less than three years (hazard ratio, 3.7), Gleason score 7 (hazard ratio, 3), and a total of three or more positive cores (hazard ratio, 2.7). The intermediate-risk group was at higher risk for metastasis, but no increased risk was seen for patients with Gleason score 6 and prostate specific antigen greater than 10 ng/ml.

"Active surveillance appears safe in patients at low risk and in select patients at intermediate risk, particularly those with Gleason score 6 and prostate specific antigen greater than 10 ng/ml," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »